Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature
Open Access
- 15 December 2019
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 188 (2), 338-340
- https://doi.org/10.1111/bjh.16333
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpuraExpert Review of Hematology, 2019
- Thrombotic thrombocytopenic purpuraNature Reviews Disease Primers, 2017
- Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myelomaAnnals of Hematology, 2015
- Drug-induced thrombotic microangiopathy: a systematic review of published reportsBlood, 2015
- Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideLeukemia & Lymphoma, 2014
- Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosisExpert Review of Hematology, 2012
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center ExperiencePLOS ONE, 2010
- TTP disease course is independent of myeloma treatment and responseAmerican Journal of Hematology, 2010
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsMicrovascular Research, 2009
- VEGF Inhibition and Renal Thrombotic MicroangiopathyThe New England Journal of Medicine, 2008